By David Michaels
In the wake of the debacles involving Vioxx, Ketek, and other dangerous drugs that should never have been approved in the first place, Congress is about to take up reauthorization of the user fee system that funds the Food and Drug Administrationâs drug review process. The system is governed by the Prescription Drug User Fee Act (PDUFA), which will expire this year. The FDA has asked Congress to reauthorize the program for five more years.
Yesterday, a group of 22 experts on drug safety and regulation issued an open letter to lawmakers asking them not to reauthorize the PDUFA because, as we write “user fees may appear to save the taxpayers money, but at an unacceptable cost to public health.”
The signers include several of the nation’s top drug safety experts (Jerry Avorn, Curt Furberg, Steve Nissen, Eric Topol, Bruce Psaty and several members of the recent Institute of Medicine panel on drug safety), former medical journal editors (Marcia Angell, Jerry Kassirer, Arnold Relman) and former top FDA and HHS staff. The energy behind the letter came from Susan Wood, of the Project on Scientific Knowledge and Public Policy (SKAPP) and former head of the FDAâs Office of Womenâs Health.
The SKAPP website has more background on the letter. Here’s what the letter says:
The Food and Drug Administration (FDA) is facing a serious crisis that has significant implications for the nationâs health.
The panel of experts recently convened by the Institute of Medicine (IOM) identified serious problems in the nationâs capacity to determine drug safety and made a series of recommendations, calling on the FDA to âembrace a culture of safety in which the risk and benefits of medications are examined during their entire market life.â
The Prescription Drug User-Fee Act (PDUFA), in which brand name drug manufacturers pay a fee for each new drug the agency reviews, is an important cause of the difficulties faced by the FDA. Last year, this amounted to over $300 million, or over one-third of the entire budget for FDAâs Center for Drug Evaluation and Research. PDUFA has helped to foster the publicâs perception that industry has become the primary client of FDA rather than the American people; this perception has contributed to the erosion of trust in FDA.
User fees may appear to save the taxpayers money, but at an unacceptable cost to public health. In one study, PDUFA- imposed deadlines on FDA staff to complete reviews quickly are associated with subsequent withdrawals, warnings and other post-approval regulatory actions. In fact, premature approval of a drug with safety problems, or an inadequate means of detecting problems that emerge after marketing (as occurred with Vioxx) actually cost the taxpayers far more than the Treasury appears to save through user fees. The human costs of delayed detection of safety problems are considerable.
With the expiration of PDUFA this year, the FDA and PhRMA have negotiated terms for a five year reauthorization. This negotiation, completed behind closed doors, had only limited input from the public. Unfortunately, the proposal crafted by the FDA and PhRMA does not come close to addressing the problems identified by the IOM.
In February, four former FDA Commissioners agreed that the nation would be better served if Congress directly appropriated the money the FDA needs to do its job right, without the constraints imposed by PDUFA.
We oppose reauthorizing PDUFA and other user fee programs modeled after it in the form negotiated by the FDA and PhRMA; instead, we support increased direct appropriations for the FDA, as is done with most federal agencies. The supposed âsavingsâ realized through user fees make no sense in light of the added medical and economic costs that are generated by an inadequate drug safety surveillance system. Direct appropriation is the most effective way to ensure FDAâs independence and commitment to drug safety.
As called for by the IOM and a recent Government Accountability Office report on this topic, Congress and the nation must carefully re-assess the system in which drugs are developed, tested, approved and followed post-approval. Ideally, the plans for new funding sources and for new activities to improve drug safety would be completed before Sept 30, 2007. But this re-assessment cannot be done in the very short timeframe scheduled for PDUFA reauthorization.
However, if PDUFA must be reauthorized this year, in order for the nation to be able to have the substantive debate required for such an important and complex issue, we call on you to re-authorize it for no more than one year, and immediately schedule a series of hearings and investigations to examine ways to ensure that our drugs are effective and safe, and that the FDA itself is sound.
This limited re-authorized PDUFA should be structured to enable the FDA to do the best job it can in advancing the health of Americans. Any reauthorized PDUFA must have the following characteristics:
â¢ Allow FDA leadership to determine how the agency allocates the fees collected to fulfill all aspects of its mission;
â¢ Deadlines or targets for speed of review must be eliminated or modified to allow flexibility and adequate time for evaluation and analysis by reviewers.
â¢ New performance goals must be linked with safety or other public health outcomes, not just speedy approval decisions.
â¢ Adequate resources must be made available for scientific research and training for FDA scientific and medical staff, including in drug safety epidemiology and risk management.
The FDAâs mission is to protect and advance the publicâs health. As it currently exists, and would exist in its proposed form, PDUFA stands in the way of this objective.
SKAPP has put up a web page with more materials on the link between PDUFA and drug safety, and weâll be writing much more about this over the next few months.
David Michaels heads the Project on Scientific Knowledge and Public Policy (SKAPP) and is Professor and Associate Chairman in the Department of Environmental and Occupational Health, the George Washington University School of Public Health and Health Services.